Anktiva-Nogapendekin Alfa Inbakicept-Pmln
Anktiva is the first FDA-approved immunotherapy that activates the immune system to treat BCG-unresponsive non-muscle invasive bladder cancer (CIS), offering some patients a lasting complete response.
Imdelltra-Tarlatamab-Dlle
Imdelltra is used to treat adults with extensive-stage small cell lung cancer (ES-SCLC) that has returned after platinum-based chemotherapy.
Kisunla-Donanemab-Azbt
Kisunla is used to treat Alzheimer’s disease. It is an FDA-approved treatment for early symptomatic Alzheimer’s disease, including mild cognitive impairment and the mild dementia stage of the condition.
Alhemo-Concizumab-Mtci
Alhemo is a preventive injection for people with hemophilia A or B with inhibitors, aged 12 and above. It helps reduce and prevent bleeding episodes by regulating the clotting pathway.
Piasky-Crovalimab-Akkz
Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.
Datroway-Datopotamab Deruxtecan-Dlnk
Datroway is an antibody-drug conjugate for adults with advanced non-small cell lung cancer that has an EGFR mutation and progressed after standard treatment. It delivers targeted chemotherapy directly to cancer cells to control tumor growth.
Bizengri-Zenocutuzumab-Zbco
Bizengri is an IV antibody therapy for adults with advanced non-small cell lung cancer or pancreatic cancer driven by NRG1 gene fusions, used after standard treatments fail. It blocks the fusion protein’s signaling to help shrink tumors and control disease progression
Vyloy-Zolbetuximab-Clzb
Vyloy is used with fluoropyrimidine and platinum-based chemotherapy as the first-line treatment for HER2-negative gastric or gastroesophageal junction cancer, which cannot be removed by surgery or has spread and tests positive for claudin (CLDN)18.2.
Ziihera-Zanidatamab-Hrii
Ziihera is the first and only approved bispecific antibody drug. It treats unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. This drug is given to patients who have already received the other chemotherapeutic treatment.
Unloxcyt-Cosibelimab-Ipdl
Unloxcyt is an IV anti–PD-L1 antibody for adults with advanced or metastatic cutaneous squamous cell carcinoma who are not surgical or radiation candidates. It helps the immune system fight cancer by blocking PD-L1, with a documented response in nearly half of patients.
